Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan in MET-Amplified Solid Tumors
NCT07196644Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 5
01
Overview
A Phase 2 trial of telisotuzumab adizutecan in solid tumor, sponsored by AbbVie Inc.. Started Dec 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07196644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196644.